A trial was designed to examine the combination of UFT and mitomycin (Mutamycin) plus tamoxifen (Nolvadex) as postoperative adjuvant therapy in the treatment of patients with stage II, estrogen receptor (ER)-positive
Yoshinobu Hata, MD, PhD
Advertisement
Articles by Yoshinobu Hata, MD, PhD
Advertisement
Latest Updated Articles
- UFT and Mitomycin Plus Tamoxifen for Stage II, ER-Positive Breast Cancer
Published: July 1st 1999 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Neoadjuvant Pembrolizumab/Radiotherapy Earns EU Approval in HNSCC Group
2
Pembrolizumab/Belzutifan Improves DFS in ccRCC Following Nephrectomy
3
What is the Impact of the SHARON Trial on Pancreatic Cancer Research?
4
3 Things You Should Know About Single-Agent ADCs in TNBC Treatment
5
